Immunotherapy summit brings together patients, experts
The NCI-designated Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine is hosting a free educational program for cancer patients and their caregivers seeking to learn more about cancer immunotherapy and clinical trials.
The Immunotherapy Patient Summit, organized by the Cancer Research Institute, a nonprofit organization dedicated to advancing immunotherapy for all types of cancer, and hosted at Baylor College of Medicine, offers education and information on immunotherapy treatment and research, patient perspectives on immunotherapy clinical trials and breakout sessions providing a deeper dive in to head and neck cancer, lung cancer and melanoma. The program will take place Jan. 27, 2018, at Baylor College of Medicine in Houston. Registration will begin at 9 a.m., and the day will conclude at 3:30 p.m.
Dr. Andrew Sikora, vice chair for research and co-director of the Head and Neck Cancer Program at Baylor, and Dr. Carlos Ramos, associate professor in the Center for Cell and Gene Therapy at Baylor, Texas Children’s Hospital and Houston Methodist and member of the Dan L Duncan Comprehensive Cancer Center at Baylor, will join other expert scientists and clinicians for the half-day event to discuss the latest cancer research and treatment focused exclusively on immunotherapy.
Attendees will have an opportunity to interact with participating experts, hear from patients who have benefited from immunotherapy and interact with others from their community. Patients also can meet with clinical trial navigators who can help connect them to immunotherapy trials for which they might be eligible.
“Patients know that immunotherapies are an exciting and fast-moving area, but are often hungry for more information about how these approaches work and whether they can be applied to their particular cancer type,” Sikora said. “The Summit will provide a forum to answer these questions and begin a dialog with patients and their providers, which will help to demystify immunotherapy treatments and related clinical trials.”
“CRI has dedicated more than six decades to advancing the science of immunotherapy with the ultimate goal of harnessing our immune system’s potential to cure all cancers, and we have reached a critical point where patients are playing an even greater role in the success of these efforts,” said Dr. Jill O’Donnell-Tormey, CEO and director of scientific affairs at the Cancer Research Institute.
Patients, caregivers and advocates interested in participating in the free educational summit can get more information.